These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 33302114)

  • 1. Dynamic changes in circulating PD-1
    Kim CG; Hong MH; Kim KH; Seo IH; Ahn BC; Pyo KH; Synn CB; Yoon HI; Shim HS; Lee YI; Choi SJ; Lee YJ; Kim EJ; Kim Y; Kwak JE; Jung J; Park SH; Paik S; Shin EC; Kim HR
    Eur J Cancer; 2021 Jan; 143():113-126. PubMed ID: 33302114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
    Kim CG; Kim G; Kim KH; Park S; Shin S; Yeo D; Shim HS; Yoon HI; Park SY; Ha SJ; Kim HR
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34907028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer.
    Kim CG; Kim KH; Pyo KH; Xin CF; Hong MH; Ahn BC; Kim Y; Choi SJ; Yoon HI; Lee JG; Lee CY; Park SY; Park SH; Cho BC; Shim HS; Shin EC; Kim HR
    Ann Oncol; 2019 Jul; 30(7):1104-1113. PubMed ID: 30977778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8
    Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The First-week Proliferative Response of Peripheral Blood PD-1
    Kim KH; Cho J; Ku BM; Koh J; Sun JM; Lee SH; Ahn JS; Cheon J; Min YJ; Park SH; Park K; Ahn MJ; Shin EC
    Clin Cancer Res; 2019 Apr; 25(7):2144-2154. PubMed ID: 30647082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD161
    Qu J; Li Y; Wu B; Shen Q; Chen L; Sun W; Wang B; Ying L; Wu L; Zhou H; Zhou J; Zhou J
    Oncoimmunology; 2024; 13(1):2371575. PubMed ID: 38952673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TCR Repertoire Diversity of Peripheral PD-1
    Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
    Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer.
    Hummelink K; van der Noort V; Muller M; Schouten RD; van den Heuvel MM; Thommen DS; Smit EF; Meijer GA; Monkhorst K
    PLoS One; 2024; 19(7):e0293707. PubMed ID: 39083541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combined model of serum neutrophil extracellular traps, CD8
    Guo J; Shu T; Zhang H; Huang N; Ren J; Lin L; Wu J; Wang Y; Huang Z; Bin J; Liao Y; Shi M; Liao W; Huang N
    FEBS J; 2024 Aug; 291(15):3403-3416. PubMed ID: 38661680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy.
    Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
    J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Jung EH; Jang HR; Kim SH; Suh KJ; Kim YJ; Lee JH; Chung JH; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
    Thorac Cancer; 2021 Mar; 12(5):619-630. PubMed ID: 33458968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC.
    Chen Y; Shao Z; Hao Z; Xin Z; Chen X; Huang L; Chen D; Lin M; Liu Q; Xu X; Li J; Wu D; Yan J; Chai Y; Wu P
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39134346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
    Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC.
    Ohue Y; Kurose K; Karasaki T; Isobe M; Yamaoka T; Futami J; Irei I; Masuda T; Fukuda M; Kinoshita A; Matsushita H; Shimizu K; Nakata M; Hattori N; Yamaguchi H; Fukuda M; Nozawa R; Kakimi K; Oka M
    J Thorac Oncol; 2019 Dec; 14(12):2071-2083. PubMed ID: 31449889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
    Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
    Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study.
    Du X; Wen S; Shi R; Xia J; Wang R; Zhang Y; Pan B; Wu X; Zhu W; Feng J; Wang X; Shen B
    BMC Cancer; 2023 Jan; 23(1):83. PubMed ID: 36698098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137
    Ugolini A; Zizzari IG; Ceccarelli F; Botticelli A; Colasanti T; Strigari L; Rughetti A; Rahimi H; Conti F; Valesini G; Marchetti P; Nuti M
    EBioMedicine; 2020 Dec; 62():103098. PubMed ID: 33166793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer.
    Ku BM; Kim Y; Lee KY; Kim SY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Eur J Immunol; 2021 Apr; 51(4):956-964. PubMed ID: 33506525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.